Kesimpta (ofatumumab)

pCPA File Number: 21407
Negotiation Status:
Concluded with an LOI
Indication(s):
Multiple Sclerosis, Relapsing-Remitting
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
SR0657-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: